Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Intellia Therapeutics (NASDAQ:NTLA), a clinical-stage gene editing company, announced the granting of inducement awards to six new employees on June 1, 2025. The awards, issued under Intellia's 2024 Inducement Plan, consist of time-based restricted stock units (RSUs) for 33,600 shares of common stock. The RSUs will vest in three equal installments on June 1 of 2026, 2027, and 2028, contingent on continued employment. These awards were granted outside the company's stockholder-approved equity incentive plans and were approved by Intellia's compensation committee in compliance with Nasdaq Listing Rule 5635(c)(4).

CAMBRIDGE, Mass., June 05, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on June 1, 2025, it awarded an inducement grant to six new employees under Intellia’s 2024 Inducement Plan as a material inducement to employment.

The inducement grant consisted of time-based restricted stock units (“RSUs”) for 33,600 shares of Intellia’s common stock, with one-third of such RSUs vesting on June 1, 2026, 2027 and 2028.

All equity vesting is subject to each employee’s continued service as an employee of, or other service provider to, Intellia through the applicable vesting dates.

All of the above-described awards were granted outside of Intellia’s stockholder-approved equity incentive plans pursuant to Intellia’s 2024 Inducement Plan, which was adopted by the board of directors in June 2024. These awards were approved by Intellia’s compensation committee as a material inducement to entering into employment with Intellia in accordance with Nasdaq Listing Rule 5635(c)(4).

About Intellia Therapeutics

Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies. Since its inception, Intellia has focused on leveraging gene editing technology to develop novel, first-in-class medicines that address important unmet medical needs and advance the treatment paradigm for patients. Intellia’s deep scientific, technical and clinical development experience, along with its people, is helping set the standard for a new class of medicine. To harness the full potential of gene editing, Intellia continues to expand the capabilities of its CRISPR-based platform with novel editing and delivery technologies. Learn more at intelliatx.com and follow us @intelliatx.

Intellia Contacts:

Investors:
Brittany Chaves
Senior Manager, Investor Relations
brittany.chaves@intelliatx.com

FAQ

What type of stock awards did Intellia Therapeutics (NTLA) grant to new employees in June 2025?

Intellia granted time-based restricted stock units (RSUs) for 33,600 shares of common stock to six new employees under its 2024 Inducement Plan.

What is the vesting schedule for Intellia's (NTLA) June 2025 inducement grants?

The RSUs will vest in three equal installments on June 1 of 2026, 2027, and 2028, subject to continued employment with Intellia.

How many employees received inducement grants from Intellia Therapeutics (NTLA) in June 2025?

Six new employees received inducement grants from Intellia Therapeutics.

Under which rule were Intellia's (NTLA) inducement grants approved?

The inducement grants were approved under Nasdaq Listing Rule 5635(c)(4) as material inducement to employment.